Table 1 Clinical characteristics of KRAS mutant NSCLC treated with immunotherapy and chemotherapy
Baseline characteristics | Immunotherapy | Chemotherapy | P value |
|---|---|---|---|
Age (year) | Â | Â | 0.02 |
  < 65 | 7(14.00%) | 36(31.30%) |  |
  ≥ 65 | 43(86.00%) | 79(68.70%) |  |
Sex | Â | Â | 0.261 |
 Male | 41(82.00%) | 85(73.91%) |  |
 Female | 9(18.00%) | 30(26.09%) |  |
Smoking history | Â | Â | 0.733 |
 Yes | 33(66.00%) | 79(68.70%) |  |
 No | 17(34.00%) | 36(31.30%) |  |
Histology | Â | Â | 0.107 |
 Adenocarcinoma | 43(86.00%) | 109(94.78%) |  |
 Squamous | 5(10.00%) | 6(5.22%) |  |
 Other | 2(4.00%) | 0(0.00%) |  |
KRAS mutant subtypes | Â | Â | 0.003 |
 G12C | 24(48.00%) | 27(24.55%) |  |
 non-G12C | 26(52.00%) | 83(75.45%) |  |
TP53 co-mutation | Â | Â | 0.853 |
 positive | 15(38.46%) | 17(40.48%) |  |
 negative | 24(61.54%) | 25(59.52%) |  |
PD-L1 expression | Â | Â | 0.022 |
  < 1% | 5(11.11%) | 13(30.95%) |  |
  ≥ 1% | 40(88.89%) | 29(69.05%) |  |
PS score | Â | Â | 0.842 |
 0–1 | 46(92.00%) | 103(89.57%) |  |
  = 2 | 4(8.00%) | 12(10.43%) |  |
Stage | Â | Â | 0.644 |
 III | 6(12.00%) | 16(13.91%) |  |
 IVa | 26(52.00%) | 66(57.39%) |  |
 IVb | 18(36.00%) | 33(28.70%) |  |